FAQ: Aditxt Inc. CEO Presentation at Wall Street Reporter’s NEXT SUPER STOCK Event

What is the main topic of the presentation by Aditxt Inc.’s CEO?

The main topic is Aditxt’s innovation acceleration model, including updates on its autoimmunity and early cancer detection programs, and the latest on the company’s pending acquisition of Evofem Biosciences, Inc.

When and where is the NEXT SUPER STOCK livestream event taking place?

The event is scheduled for June 26, 2025, at 1:00 p.m. ET, hosted by Wall Street Reporter.

Who is presenting at the NEXT SUPER STOCK event?

Amro Albanna, Co-founder and CEO of Aditxt Inc., will be presenting.

What is Aditxt Inc.’s mission?

Aditxt’s mission is to ‘Make Promising Innovations Possible Together’ by accelerating health innovations through its ecosystem of research institutions, industry partners, and shareholders.

What programs does Aditxt currently operate?

Aditxt operates two programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

What are the conditions for the closing of the transactions with Appili and Evofem?

The conditions include approval by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.

Where can I find more information about Aditxt Inc.?

More information is available at www.Aditxt.com and in the company’s newsroom at https://ibn.fm/ADTX.

What is the significance of Aditxt’s pending acquisition of Evofem Biosciences, Inc.?

The acquisition is part of Aditxt’s strategy to expand its health innovation programs, specifically in women’s health, by integrating Evofem’s focus on infectious diseases.